Prelude Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Prelude Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.89M	Buy	+54,825	New	+$2.25M	0.22%	111
2025 Q2	–	Sell	-17,500	Closed	-$48.3K	–	1347
2025 Q1	$48.3K	Buy	+17,500	New	+$71.5K	﹤0.01%	1094
2024 Q4	–	Sell	-18,778	Closed	-$157K	–	1559
2024 Q3	$157K	Sell	18,778 -13,309	-41%	-$110K	0.01%	1101
2024 Q2	$219K	Sell	32,087 -52,532	-62%	-$318K	0.02%	949
2024 Q1	$555K	Buy	+84,619	New	+$553K	0.03%	592
2022 Q4	–	Sell	-10,945	Closed	-$64K	–	1607
2022 Q3	$64K	Buy	+10,945	New	+$40.7K	﹤0.01%	1213

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Prelude Capital Management's TERN Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 54,825 shares worth $2.89M. The stake represents 0.22% of the portfolio and ranks #111 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in TERN as recently as Q1 2025.

Prelude Capital Management first reported a position in TERN in Q3 2022 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Prelude Capital Management held 54,825 shares of Terns Pharmaceuticals worth $2.89M as of Q1 2026.
Terns Pharmaceuticals was a new Prelude Capital Management position in Q1 2026.
Terns Pharmaceuticals made up 0.22% of Prelude Capital Management's portfolio in Q1 2026, its #111 holding.
Prelude Capital Management first reported a position in Terns Pharmaceuticals in Q3 2022 and has held it in 6 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.